Jiangsu Bioperfectus Technologies Co Ltd (688399) - Total Assets
Based on the latest financial reports, Jiangsu Bioperfectus Technologies Co Ltd (688399) holds total assets worth CN¥3.65 Billion CNY (≈ $533.91 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jiangsu Bioperfectus Technologies Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Jiangsu Bioperfectus Technologies Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Jiangsu Bioperfectus Technologies Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jiangsu Bioperfectus Technologies Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Bioperfectus Technologies Co Ltd's total assets of CN¥3.65 Billion consist of 57.2% current assets and 42.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 21.7% |
| Accounts Receivable | CN¥59.08 Million | 1.6% |
| Inventory | CN¥67.04 Million | 1.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥27.45 Million | 0.7% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Jiangsu Bioperfectus Technologies Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jiangsu Bioperfectus Technologies Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Bioperfectus Technologies Co Ltd's current assets represent 57.2% of total assets in 2024, a decrease from 85.2% in 2016.
- Cash Position: Cash and equivalents constituted 21.7% of total assets in 2024, up from 4.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 1.8% of total assets.
Jiangsu Bioperfectus Technologies Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Bioperfectus Technologies Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥7.26 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥38.02 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $504.60 Million |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $563.83 Million |
Jiangsu Bioperfectus Technologies Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.32 | 5.19 | 3.41 |
| Quick Ratio | 3.22 | 4.96 | 3.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.25 Billion | CN¥1.85 Billion | CN¥1.26 Billion |
Jiangsu Bioperfectus Technologies Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Bioperfectus Technologies Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | CN¥3.74 Billion |
| Market Capitalization | $739.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Bioperfectus Technologies Co Ltd's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jiangsu Bioperfectus Technologies Co Ltd's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jiangsu Bioperfectus Technologies Co Ltd (2016–2024)
The table below shows the annual total assets of Jiangsu Bioperfectus Technologies Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.74 Billion ≈ $547.27 Million |
-4.26% |
| 2023-12-31 | CN¥3.91 Billion ≈ $571.63 Million |
-20.13% |
| 2022-12-31 | CN¥4.89 Billion ≈ $715.71 Million |
+39.77% |
| 2021-12-31 | CN¥3.50 Billion ≈ $512.06 Million |
+53.64% |
| 2020-12-31 | CN¥2.28 Billion ≈ $333.30 Million |
+97.31% |
| 2019-12-31 | CN¥1.15 Billion ≈ $168.92 Million |
+191.83% |
| 2018-12-31 | CN¥395.56 Million ≈ $57.88 Million |
+27.34% |
| 2017-12-31 | CN¥310.64 Million ≈ $45.46 Million |
+8.62% |
| 2016-12-31 | CN¥285.99 Million ≈ $41.85 Million |
-- |
About Jiangsu Bioperfectus Technologies Co Ltd
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, … Read more